Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.


Circulating IP-10 and MCP-1 Levels in Active Localized Scleroderma.

Kurzinski1,  Katherine, Kelsey1,  Christina, Arkachaisri2,  Thaschawee, Feghali-Bostwick3,  Carol A., Torok1,  Kathryn S.

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
KK Women's and Children's Hosp, Singapore, Singapore
University of Pittsburgh, Pittsburgh, PA

Background/Purpose:

Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues that primarily affects children. T-helper (Th) cell subsets and their associated cytokines are thought to contribute to the pathogenesis of LS and systemic sclerosis (SSc). Traditionally, a Th2 predominant response has been supported, but more recent data also implicate Th1, Th17, and various chemokine involvement. This study was designed to further evaluate the serum cytokine and chemokine profiles of patients with active pediatric LS.

Methods:

Serum samples were obtained from pediatric LS, adult LS, pediatric SSc patients and healthy pediatric controls. All LS patients had active disease at the time of sample collection, defined clinically by the presence of new, expanding, and/or erythematous lesions, and were naïve to systemic therapy. Using Luminex technology, 27 cytokines and chemokines from Th1, Th2, and Th17 subsets were evaluated. Nonparametric analyses were performed to compare cytokine/chemokine levels between groups and to determine relationships between individual analyte levels and clinical parameters p < 0.05.

Results:

Circulating levels of IP-10 and MCP-1 were significantly elevated in pediatric LS, adult LS, and pediatric SSc when compared with healthy controls (see Table). IP-10 levels correlated with mLOSDI, a validated skin damage measure for LS patients (rs=0.644, p=0.001), and with the number of anatomical sites affected (rs=0.515, p=0.012). IP-10 levels were also significantly higher in LS patients with positive single stranded DNA (ssDNA) antibodies.

GroupnIP-10 (pg/ml)
Median
IQRMCP-1 (pg/ml)
Median
IQR
Pediatric LS23407.59201.99–1278.93371.17341.55–577.01
Adult LS32358.72233.68–1435.05652.5415.97–938.58
Pediatric SSc11435.47262.04–779.76843.65472.14–2101.77
Healthy Control10208.08124.81–259.08132.8974.33–214.34

Conclusion:

Elevated levels of IP-10, an IFN-g-associated chemokine, and MCP-1, a profibrotic chemokine, were seen in pediatric and adult LS and SSc, suggestive of a shared pathogenesis between the diseases. Moderate to strong correlations were observed between IP-10 levels and the number of sites affected and ssDNA antibodies, indicating that IP-10 may be a predictor of disease severity in LS patients. Future investigation into the roles of IP-10 and MCP-1 and their association with Th cell lineages in LS will help lead to a greater understanding of the disease pathogenesis and to the development of more efficacious therapies.

To cite this abstract, please use the following information:
Kurzinski, Katherine, Kelsey, Christina, Arkachaisri, Thaschawee, Feghali-Bostwick, Carol A., Torok, Kathryn S.; Circulating IP-10 and MCP-1 Levels in Active Localized Scleroderma. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :308
DOI:

Abstract Supplement

Meeting Menu

2011 ACR/ARHP